Lassogen, Inc.
Selective endothelin receptor type B (ETBR) antagonist lasso peptides for immunotherapy enhancement in cancer
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2019
- Latest Form D
- $5.1M, Sep 2020
- Total capital
- $5.7M
- Federal grants
- $625K
- 2 awards · 2020–2021
- Rank in peer group#140 of 502
- Private capital raised
- $5.1M
- 1 Form D · last Sep 2020
- 73 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 20 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of Lasso Peptides as Potent Endothelin Receptor B Antagonists for Immuno-oncology$400K
- Private capital raisedForm D · SEC · 1st filing$5.1M
- Federal grantHealth and Human S · Phase I · A Genes-to-Molecules Platform for Expanding Natural Product Diversity$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
3months
from Lassogen, Inc.’s first federal award to its first private round.
- First federal award · Jun 2020
- Health and Human S · $225K
- First Form D · Sep 2020
- $5.1M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#140 · top 28%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Mark J BurkResearcherExecutive OfficerLinked by $625K in grants as PI
What it has protected
USPTO · 0 granted of 20- PendingMethods And Biological Systems For Discovering And Optimizing Lasso PeptidesUSPTOApplication 17906102
- PendingLasso Peptides For Treatment Of CancerUSPTOApplication 17790103
- PendingSystems And Methods For Discovering And Optimizing Lasso PeptidesUSPTOApplication 17296372
Show all 20 patent records
- Methods And Biological Systems For Discovering And Optimizing Lasso PeptidesApr 13, 2023 · Application 17906102Pending
- Lasso Peptides For Treatment Of CancerMar 9, 2023 · Application 17790103Pending
- Systems And Methods For Discovering And Optimizing Lasso PeptidesFeb 3, 2022 · Application 17296372Pending
- Methods For Producing, Discovering, And Optimizing Lasso PeptidesJan 28, 2021 · Application 17043605Pending
- Integrated And Iterative Methods For Designing, Identifying And Optimizing Lasso PeptidesApplication 63612963Pending
- Lasso Peptide Integrin InhibitorsApplication 63612957Pending
- Lasso Peptides As Endothelin B Receptor AntagonistsApplication PCTUS2023065031Pending
- Lasso Peptides As Endothelin B Receptor AntagonistsApplication 63325465Pending
- Methods And Biological Systems For Discovering And Optimizing Lasso PeptidesApplication PCTUS2021023000Pending
- Lasso Peptides For Treatment Of CancerApplication PCTUS2021012191Pending
- Methods And Biological Systems For Discovering And Optimizing Lasso PeptidesApplication 62992105Pending
- Lasso Peptides For Treatment Of CancerApplication 62980918Pending
- Lasso Peptides For Treatment Of CancerApplication 62957762Pending
- Systems And Methods For Discovering And Optimizing Lasso PeptidesApplication PCTUS2019065244Pending
- Methods For Producing, Discovering, And Optimizing Lasso PeptidesApplication PCTUS2019024811Pending
- Engineered Lasso CyclasesApplication PCTUS2025019776Pending
- Systems And Methods For Discovering And Optimizing Lasso PeptidesApplication 62777702Pending
- Lasso Peptide Integrin InhibitorsApplication PCTUS2024061371Pending
- Integrated And Iterative Methods For Designing, Identifying And Optimizing Lasso PeptidesApplication PCTUS2024061377Pending
- Engineered Lasso CyclasesApplication 63564911Pending
Related companies, and why
- SIGNUM BIOSCIENCESSimilar federal contract value in Biotech · null in contracts
- OMVAX, INC.Similar federal contract value in Biotech · null in contracts
- HERA TESTING LABORATORIES, INC.Similar federal contract value in Biotech · null in contracts
- ONC.AI, INC.Similar federal contract value in Biotech · null in contracts
- PROMAKHOS THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- SYNTIS BIO INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .